XWARSPH
Market cap364mUSD
Dec 20, Last price
12.25PLN
1D
-3.92%
1Q
-3.16%
Name
Sopharma AD
Chart & Performance
Profile
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company's products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of functions of the sexual system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions. It also trades in food supplements; provides secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; and purchases, collects, grows, produces, and trades in herbs and medicinal plants. In addition, the company engages in the retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers market and public opinion research services; and engages in non-pharma activities, such as veterinary vaccines, infusion solutions. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
Valuation
Title BGN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 1,887,947 13.53% | 1,662,992 3.72% | 1,603,310 11.43% | |||||||
Cost of revenue | 1,727,791 | 1,358,099 | 1,320,151 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 160,156 | 304,893 | 283,159 | |||||||
NOPBT Margin | 8.48% | 18.33% | 17.66% | |||||||
Operating Taxes | 11,821 | 9,153 | 5,871 | |||||||
Tax Rate | 7.38% | 3.00% | 2.07% | |||||||
NOPAT | 148,335 | 295,740 | 277,288 | |||||||
Net income | 95,207 33.87% | 71,121 -20.53% | 89,496 200.27% | |||||||
Dividends | (71,889) | (11) | (63) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 150,041 | (1,840) | (4,116) | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 223,638 | 169,295 | 238,442 | |||||||
Long-term debt | 181,123 | 192,904 | 136,850 | |||||||
Deferred revenue | 6,155 | 6,783 | ||||||||
Other long-term liabilities | 39,116 | 19,381 | 22,876 | |||||||
Net debt | 40,465 | 174,923 | 204,517 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 45,033 | 124,622 | (75,963) | |||||||
CAPEX | (24,390) | (23,219) | (27,110) | |||||||
Cash from investing activities | (62,849) | (63,171) | (68,065) | |||||||
Cash from financing activities | 126,845 | (64,342) | 156,606 | |||||||
FCF | 216,418 | 304,058 | 309,544 | |||||||
Balance | ||||||||||
Cash | 128,791 | 19,654 | 37,677 | |||||||
Long term investments | 235,505 | 167,622 | 133,098 | |||||||
Excess cash | 269,899 | 104,126 | 90,610 | |||||||
Stockholders' equity | 810,285 | 702,955 | 645,555 | |||||||
Invested Capital | 855,921 | 910,086 | 913,408 | |||||||
ROIC | 16.80% | 32.44% | 29.65% | |||||||
ROCE | 14.23% | 29.89% | 27.97% | |||||||
EV | ||||||||||
Common stock shares outstanding | 140,196 | 121,494 | 125,368 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 212,229 | 356,961 | 333,778 | |||||||
EV/EBITDA | ||||||||||
Interest | 10,213 | 6,009 | 10,791 | |||||||
Interest/NOPBT | 6.38% | 1.97% | 3.81% |